Copertino DC Jr, Holmberg CS, Weiler J, Ward AR, Howard JN, Levinger C, Pang AP, Corley MJ, Dündar F, Zumbo P, Betel D, Gandhi RT, McMahon DK, Bosch RJ, Linden N, Macatangay BJ, Cyktor JC, Eron JJ, Mellors JW, Kovacs C, Benko E, Bosque A, Jones RB. The latency reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific CD8+ T-cells. JCI Insight. 2023 Aug 15:e169028. doi: 10.1172/jci.insight.169028. Epub ahead of print. PMID: 37581929.

Mutascio S, Mota T, Franchitti L, Sharma AA, Willemse A, Bergstresser SN, Wang H, Statzu M, Tharp GK, Weiler J, Sékaly RP, Bosinger SE, Paiardini M, Silvestri G, Jones RB, Kulpa DA. CD8+ T cells promote HIV latency by remodeling CD4+ T cell metabolism to enhance their survival, quiescence, and stemness. Immunity. 2023 May 9;56(5):1132-1147.e6. doi: 10.1016/j.immuni.2023.03.010. Epub 2023 Apr 7. PMID: 37030290.

Gunst JD, Pahus MH, Rosás-Umbert M, Lu IN, Benfield T, Nielsen H, Johansen IS, Mohey R, Østergaard L, Klastrup V, Khan M, Schleimann MH, Olesen R, Støvring H, Denton PW, Kinloch NN, Copertino DC, Ward AR, Alberto WDC, Nielsen SD, Puertas MC, Ramos V, Reeves JD, Petropoulos CJ, Martinez-Picado J, Brumme ZL, Jones RB, Fox J, Tolstrup M, Nussenzweig MC, Caskey M, Fidler S, Søgaard OS. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. Nat Med. 2022 Oct 17. doi: 10.1038/s41591-022-02023-7. Epub ahead of print. PMID: 36253609.

Ward AR, Thomas AS, Stevenson EM, Huang SH, Keating SM, Gandhi RT, McMahon DK, Bosch RJ, Macatangay BJ, Cyktor JC, Eron JJ, Mellors JW, Jones RB; ACTG A5321 Team. No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART. AIDS. 2022 Oct 1;36(12):1617-1628. doi: 10.1097/QAD.0000000000003301. Epub 2022 Jun 22. PMID: 35730388; PMCID: PMC9444951.

Zhang F, Zang TM, Stevenson EM, Lei X, Copertino DC, Mota TM, Boucau J, Garcia-Beltran WF, Jones RB, Bieniasz PD. Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins. Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2209042119. doi: 10.1073/pnas.2209042119. Epub 2022 Sep 22. PMID: 36136978.

Stevenson EM, Terry S, Copertino D, Leyre L, Danesh A, Weiler J, Ward AR, Khadka P, McNeil E, Bernard K, Miller IG, Ellsworth GB, Johnston CD, Finkelsztein EJ, Zumbo P, Betel D, Dündar F, Duncan MC, Lapointe HR, Speckmaier S, Moran-Garcia N, Papa MP, Nicholes S, Stover CJ, Lynch RM, Caskey M, Gaebler C, Chun TW, Bosque A, Wilkin TJ, Lee GQ, Brumme ZL, Jones RB. SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells. Nat Commun. 2022 Aug 19;13(1):4888. doi: 10.1038/s41467-022-32376-z. PMID: 35985993; PMCID: PMC9389512.

Linden N, Jones RB. Potential multi-modal effects of provirus integration on HIV-1 persistence: lessons from other viruses. Trends Immunol. 2022 Aug;43(8):617-629. doi: 10.1016/j.it.2022.06.001. Epub 2022 Jul 8. PMID: 35817699; PMCID: PMC9429957.

Leyre L, Jones RB. Hide and seek: for HIV-infected CD4+ T cells, playing well comes with maturity. J Clin Invest. 2022 Apr 1;132(7):1-4. doi: 10.1172/JCI158872. PMID: 35362485; PMCID: PMC8976498.

Ivison GT, Vendrame E, Martínez-Colón GJ, Ranganath T, Vergara R, Zhao NQ, Martin MP, Bendall SC, Carrington M, Cyktor JC, McMahon DK, Eron J, Jones RB, Mellors JW, Bosch RJ, Gandhi RT, Holmes S, Blish CA; ACTG 5321 Team. Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients. Front Cell Infect Microbiol. 2022 Feb 10;12:757846. doi: 10.3389/fcimb.2022.757846. PMID: 35223535; PMCID: PMC8866573.

Kinloch NN, Ren Y, Conce Alberto WD, Dong W, Khadka P, Huang SH, Mota TM, Wilson A, Shahid A, Kirkby D, Harris M, Kovacs C, Benko E, Ostrowski MA, Del Rio Estrada PM, Wimpelberg A, Cannon C, Hardy WD, MacLaren L, Goldstein H, Brumme CJ, Lee GQ, Lynch RM, Brumme ZL, Jones RB. HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). Nat Commun. 2021 Jan 8;12(1):165. doi: 10.1038/s41467-020-20442-3. Erratum in: Nat Commun. 2021 May 13;12(1):2958. PMID: 33420062; PMCID: PMC7794580.

Ward AR, Mota TM, Jones RB. Immunological approaches to HIV cure. Semin Immunol. 2021 Jan;51:101412. doi: 10.1016/j.smim.2020.101412. Epub 2020 Sep 24. PMID: 32981836.

McCann CD, van Dorp CH, Danesh A, Ward AR, Dilling TR, Mota TM, Zale E, Stevenson EM, Patel S, Brumme CJ, Dong W, Jones DS, Andresen TL, Walker BD, Brumme ZL, Bollard CM, Perelson AS, Irvine DJ, Jones RB. A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. J Exp Med. 2021 Jul 5;218(7):e20201908. doi: 10.1084/jem.20201908. Epub 2021 May 14. PMID: 33988715; PMCID: PMC8129803.

Stevenson EM, Ward AR, Truong R, Thomas AS, Huang SH, Dilling TR, Terry S, Bui JK, Mota TM, Danesh A, Lee GQ, Gramatica A, Khadka P, Alberto WDC, Gandhi RT, McMahon DK, Lalama CM, Bosch RJ, Macatangay B, Cyktor JC, Eron JJ, Mellors JW, Jones RB; AIDS Clinical Trials Group A5321 Team. HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. JCI Insight. 2021 Feb 8;6(3):e142640. doi: 10.1172/jci.insight.142640. PMID: 33400687; PMCID: PMC7934865.

Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, Lambotte O, Lamplough R, Ndung'u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR; International AIDS Society (IAS) Global Scientific Strategy working group. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy. 2021. Nat Med. 2021 Dec;27(12):2085-2098. doi: 10.1038/s41591-021-01590-5. Epub 2021 Dec 1. PMID: 34848888.

Ren Y, Huang SH, Patel S, Alberto WDC, Magat D, Ahimovic D, Macedo AB, Durga R, Chan D, Zale E, Mota TM, Truong R, Rohwetter T, McCann CD, Kovacs CM, Benko E, Wimpelberg A, Cannon C, Hardy WD, Bosque A, Bollard CM, Jones RB. BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo. J Clin Invest. 2020 May 1;130(5):2542-2559. doi: 10.1172/JCI132374. PMID: 32027622; PMCID: PMC7191002.

Patel S, Hanajiri R, Grant M, Saunders D, Van Pelt S, Keller M, Hanley PJ, Simon G, Nixon DF, Hardy D, Jones RB, Bollard CM. HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing Platform. Mol Ther Methods Clin Dev. 2019 Oct 11;16:11-20. doi: 10.1016/j.omtm.2019.10.001. PMID: 31720305; PMCID: PMC6838524.

Mota TM, McCann CD, Danesh A, Huang SH, Magat DB, Ren Y, Leyre L, Bui TD, Rohwetter TM, Kovacs CM, Benko E, MacLaren L, Wimpelberg A, Cannon CM, Hardy WD, Safrit JT, Jones RB. Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8+ T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal. J Virol. 2020 Apr 16;94(9):e01845-19. doi: 10.1128/JVI.01845-19. PMID: 32051267; PMCID: PMC7163115.

Danesh A, Ren Y, Brad Jones R. Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV. Curr Opin HIV AIDS. 2020 Sep;15(5):316-323. doi: 10.1097/COH.0000000000000644. PMID: 32732552; PMCID: PMC7748341.

Keller MD, Harris KM, Jensen-Wachspress MA, Kankate VV, Lang H, Lazarski CA, Durkee-Shock J, Lee PH, Chaudhry K, Webber K, Datar A, Terpilowski M, Reynolds EK, Stevenson EM, Val S, Shancer Z, Zhang N, Ulrey R, Ekanem U, Stanojevic M, Geiger A, Liang H, Hoq F, Abraham AA, Hanley PJ, Cruz CR, Ferrer K, Dropulic L, Gangler K, Burbelo PD, Jones RB, Cohen JI, Bollard CM. SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood. 2020 Dec 17;136(25):2905-2917. doi: 10.1182/blood.2020008488. PMID: 33331927; PMCID: PMC7746091.

Ren Y, Korom M, Ward AR, Truong R, Chan D, Huang SH, Kovacs CM, Benko E, Safrit JT, Lee J, Garbán H, Lynch R, Jones RB. Relationships between Neutralization, Binding, and ADCC of Broadly Neutralizing Antibodies against Reservoir HIV. J Virol. 2020 Dec 22;95(2):e01808-20. doi: 10.1128/JVI.01808-20. PMID: 33115874; PMCID: PMC7944442.

Jones RB. Current challenges and recent advances in the search for a cure for HIV. J Int AIDS Soc. 2019 Feb;22(2):e25248. doi: 10.1002/jia2.25248. PMID: 30734500; PMCID: PMC6367571.

Flerin NC, Bardhi A, Zheng JH, Korom M, Folkvord J, Kovacs C, Benko E, Truong R, Mota T, Connick E, Jones RB, Lynch RM, Goldstein H. Establishment of a Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs. J Virol. 2019 Mar 5;93(6):e02051-18. doi: 10.1128/JVI.02051-18. PMID: 30626677; PMCID: PMC6401459.

Huang SH, McCann CD, Mota TM, Wang C, Lipkin SM, Jones RB. Have Cells Harboring the HIV Reservoir Been Immunoedited? Front Immunol. 2019 Aug 6;10:1842. doi: 10.3389/fimmu.2019.01842. PMID: 31447850; PMCID: PMC6691121.

Mota TM, Jones RB. HTLV-1 as a Model for Virus and Host Coordinated Immunoediting. Front Immunol. 2019 Sep 24;10:2259. doi: 10.3389/fimmu.2019.02259. PMID: 31616431; PMCID: PMC6768981.

Webb GM, Li S, Mwakalundwa G, Folkvord JM, Greene JM, Reed JS, Stanton JJ, Legasse AW, Hobbs T, Martin LD, Park BS, Whitney JB, Jeng EK, Wong HC, Nixon DF, Jones RB, Connick E, Skinner PJ, Sacha JB. The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles. Blood Adv. 2018 Jan 23;2(2):76-84. doi: 10.1182/bloodadvances.2017012971. PMID: 29365313; PMCID: PMC5787870.

Huang SH, Ren Y, Thomas AS, Chan D, Mueller S, Ward AR, Patel S, Bollard CM, Cruz CR, Karandish S, Truong R, Macedo AB, Bosque A, Kovacs C, Benko E, Piechocka-Trocha A, Wong H, Jeng E, Nixon DF, Ho YC, Siliciano RF, Walker BD, Jones RB. Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. J Clin Invest. 2018 Feb 1;128(2):876-889. doi: 10.1172/JCI97555. Epub 2018 Jan 22. PMID: 29355843; PMCID: PMC5785246.

Clutton GT, Jones RB. Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. Front Immunol. 2018 Jun 22;9:1452. doi: 10.3389/fimmu.2018.01452. PMID: 29988382; PMCID: PMC6023971.

Bachtel ND, Umviligihozo G, Pickering S, Mota TM, Liang H, Del Prete GQ, Chatterjee P, Lee GQ, Thomas R, Brockman MA, Neil S, Carrington M, Bwana B, Bangsberg DR, Martin JN, Kallas EG, Donini CS, Cerqueira NB, O'Doherty UT, Hahn BH, Jones RB, Brumme ZL, Nixon DF, Apps R. HLA-C downregulation by HIV-1 adapts to host HLA genotype. PLoS Pathog. 2018 Sep 4;14(9):e1007257. doi: 10.1371/journal.ppat.1007257. PMID: 30180214; PMCID: PMC6138419.

Jones BR, Kinloch NN, Horacsek J, Ganase B, Harris M, Harrigan PR, Jones RB, Brockman MA, Joy JB, Poon AFY, Brumme ZL. Phylogenetic approach to recover integration dates of latent HIV sequences within-host. Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8958-E8967. doi: 10.1073/pnas.1802028115. Epub 2018 Sep 5. PMID: 30185556; PMCID: PMC6156657.

Macedo AB, Resop RS, Martins LJ, Szaniawski MA, Sorensen ES, Spivak AM, Nixon DF, Jones RB, Planelles V, Bosque A. Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus. AIDS Res Hum Retroviruses. 2018 Sep;34(9):769-777. doi: 10.1089/AID.2018.0098. Epub 2018 Aug 10. PMID: 29926732; PMCID: PMC6152854.

Osuna CE, Lim SY, Kublin JL, Apps R, Chen E, Mota TM, Huang SH, Ren Y, Bachtel ND, Tsibris AM, Ackerman ME, Jones RB, Nixon DF, Whitney JB. Evidence that CD32a does not mark the HIV-1 latent reservoir. Nature. 2018 Sep;561(7723):E20-E28. doi: 10.1038/s41586-018-0495-2. Epub 2018 Sep 19. Erratum in: Nature. 2018 Nov;563(7733):E33. PMID: 30232424; PMCID: PMC6528470.

Ren Y, Korom M, Truong R, Chan D, Huang SH, Kovacs CC, Benko E, Safrit JT, Lee J, Garbán H, Apps R, Goldstein H, Lynch RM, Jones RB. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs. J Virol. 2018 Nov 12;92(23):e00895-18. doi: 10.1128/JVI.00895-18. PMID: 30209173; PMCID: PMC6232479.

Raposo RAS, de Mulder Rougvie M, Paquin-Proulx D, Brailey PM, Cabido VD, Zdinak PM, Thomas AS, Huang SH, Beckerle GA, Jones RB, Nixon DF. IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis. JCI Insight. 2017 Jan 12;2(1):e85811. doi: 10.1172/jci.insight.85811. PMID: 28097226; PMCID: PMC5214598.

Jones RB, Mueller S, Kumari S, Vrbanac V, Genel S, Tager AM, Allen TM, Walker BD, Irvine DJ. Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells. Biomaterials. 2017 Feb;117:44-53. doi: 10.1016/j.biomaterials.2016.11.048. Epub 2016 Nov 25. PMID: 27936416; PMCID: PMC5204257.

Thomas AS, Jones KL, Gandhi RT, McMahon DK, Cyktor JC, Chan D, Huang SH, Truong R, Bosque A, Macedo AB, Kovacs C, Benko E, Eron JJ, Bosch RJ, Lalama CM, Simmens S, Walker BD, Mellors JW, Jones RB. T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. PLoS Pathog. 2017 Sep 20;13(9):e1006629. doi: 10.1371/journal.ppat.1006629. PMID: 28931091; PMCID: PMC5624641.

Pollack RA, Jones RB, Pertea M, Bruner KM, Martin AR, Thomas AS, Capoferri AA, Beg SA, Huang SH, Karandish S, Hao H, Halper-Stromberg E, Yong PC, Kovacs C, Benko E, Siliciano RF, Ho YC. Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. Cell Host Microbe. 2017 Apr 12;21(4):494-506.e4. doi: 10.1016/j.chom.2017.03.008. PMID: 28407485; PMCID: PMC5433942.

Jones RB, Walker BD. HIV-specific CD8⁺ T cells and HIV eradication. J Clin Invest. 2016 Feb;126(2):455-63. doi: 10.1172/JCI80566. Epub 2016 Jan 5. PMID: 26731469; PMCID: PMC4731167.

Jones RB, Mueller S, O'Connor R, Rimpel K, Sloan DD, Karel D, Wong HC, Jeng EK, Thomas AS, Whitney JB, Lim SY, Kovacs C, Benko E, Karandish S, Huang SH, Buzon MJ, Lichterfeld M, Irrinki A, Murry JP, Tsai A, Yu H, Geleziunas R, Trocha A, Ostrowski MA, Irvine DJ, Walker BD. A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. PLoS Pathog. 2016 Apr 15;12(4):e1005545. doi: 10.1371/journal.ppat.1005545. PMID: 27082643; PMCID: PMC4833318.

Patel S, Jones RB, Nixon DF, Bollard CM. T-cell therapies for HIV: Preclinical successes and current clinical strategies. Cytotherapy. 2016 Aug;18(8):931-942. doi: 10.1016/j.jcyt.2016.04.007. Epub 2016 Jun 2. PMID: 27265874; PMCID: PMC4935558.

Ranasinghe S, Lamothe PA, Soghoian DZ, Kazer SW, Cole MB, Shalek AK, Yosef N, Jones RB, Donaghey F, Nwonu C, Jani P, Clayton GM, Crawford F, White J, Montoya A, Power K, Allen TM, Streeck H, Kaufmann DE, Picker LJ, Kappler JW, Walker BD. Antiviral CD8+ T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion. Immunity. 2016 Oct 18;45(4):917-930. doi: 10.1016/j.immuni.2016.09.015. PMID: 27760342; PMCID: PMC5077698.

Brockman MA, Jones RB, Brumme ZL. Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs. Front Immunol. 2015 Oct 2;6:506. doi: 10.3389/fimmu.2015.00506. PMID: 26483795; PMCID: PMC4591506.

Anmole G, Kuang XT, Toyoda M, Martin E, Shahid A, Le AQ, Markle T, Baraki B, Jones RB, Ostrowski MA, Ueno T, Brumme ZL, Brockman MA. A robust and scalable TCR-based reporter cell assay to measure HIV-1 Nef-mediated T cell immune evasion. J Immunol Methods. 2015 Nov;426:104-13. doi: 10.1016/j.jim.2015.08.010. Epub 2015 Aug 28. PMID: 26319395.